Following a tough opening salvo from Starboard Value last fall, Pfizer is getting a chance to catch its breath in the activist investor’s unfolding proxy fight. Starboard stopped short of ...

Activist investor Starboard Value has launched a broadside against Pfizer's leadership under chief executive Albert Bourla, claiming at least $20 billion in value – and possibly as much as $60 ...

Activist investor Starboard is backing down in its fight at Pfizer after seeing little chance of winning board seats or rousing enough shareholder pressure to force out its CEO. A deadline to ...

Jeffrey Smith’s Starboard Value disclosed in an SEC filing its holdings as of December 31, 2024. The fund’s new buys during the fourth quarter ...

Activist Starboard Value did not nominate any directors to Pfizer’s (PFE) board ahead of a January 25 deadline for the company’s annual meeting in April, Damian Garde and Crystal Tse of ...

That drug came through Pfizer’s 2022 acquisition of Global Blood Therapeutics for US$5.4bil, one of a string of purchases that Starboard considers to have delivered poor results, the person said.

Pfizer's fourth quarter beat expectations on strong sales of its Covid vaccine and pill, bolstering its sales as it seeks to ...

Activist Starboard Value has decided not to pursue a proxy battle with Pfizer. Starboard built a $1 billion stake in Pfizer in October and reportedly planned to push for changes. Get two weeks of ...

(Bloomberg) -- Pfizer Inc. got a reprieve — at least for now — in its battle with activist investor Starboard Value LP, according to people familiar with the matter. Starboard did not nominate ...

Shares of Pfizer PFE rose nearly 3% on Monday following a report issued by Bloomberg, which stated that activist investor Starboard did not nominate any director to Pfizer’s board ahead of Jan. 25.